User profiles for Richard B Warren
 | RB WarrenUniversity of manchester UK Verified email at manchester.ac.uk Cited by 14752 |
[HTML][HTML] Genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
…, H Traupe, AC Viswanathan, RB Warren… - Nature …, 2010 - ncbi.nlm.nih.gov
(WTCCC2) consortia is provided in the Supplementary Note online. Author Contributions FC,
ADB, CEMG, J. Kere., A. Reis, JNB and RCT oversaw cohort collection for both the …
ADB, CEMG, J. Kere., A. Reis, JNB and RCT oversaw cohort collection for both the …
[HTML][HTML] Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of …
Drug survival reflects a drug’s effectiveness, safety, and tolerability. We assessed the drug
survival of biologics used to treat psoriasis in a prospective national pharmacovigilance …
survival of biologics used to treat psoriasis in a prospective national pharmacovigilance …
[HTML][HTML] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double …
…, M Gooderham, RB Warren, KA Papp, B Strober… - Journal of the American …, 2023 - Elsevier
… Dr Warren has received research grants from AbbVie, Almirall, Amgen, Celgene, Eli Lilly,
Janssen, Leo Pharma, Novartis, Pfizer, and UCB and has received consulting fees from AbbVie…
Janssen, Leo Pharma, Novartis, Pfizer, and UCB and has received consulting fees from AbbVie…
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind …
Background There is an unmet need for a treatment for psoriasis that results in complete skin
clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody that …
clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody that …
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
Background The multimorbid burden and use of systemic immunosuppressants in people
with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 (…
with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 (…
Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID …
Importance Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally
because of their ability to ameliorate shared immune pathways across immune-mediated …
because of their ability to ameliorate shared immune pathways across immune-mediated …
[HTML][HTML] Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis
EJ Samarasekera, JM Neilson, RB Warren… - Journal of Investigative …, 2013 - Elsevier
The relationship between psoriasis and increased risk of cardiovascular disease (CVD) is
controversial. We critically evaluate 14 cohorts and meta-analyze the magnitude of CVD risk …
controversial. We critically evaluate 14 cohorts and meta-analyze the magnitude of CVD risk …
[HTML][HTML] Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17A and IL-17F. We assessed the efficacy and safety of bimekizumab in patients with …
(IL)-17A and IL-17F. We assessed the efficacy and safety of bimekizumab in patients with …
[HTML][HTML] Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised …
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
[HTML][HTML] Bimekizumab versus secukinumab in plaque psoriasis
K Reich, RB Warren, M Lebwohl… - … England Journal of …, 2021 - Mass Medical Soc
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both
interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with …
interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with …